Yes, I understood the prophylactic nature of the drug. It does; however, provide another tool to reduce RSV risk / severity in infants.
True. Keep in mind that there has been another monoclonal antibody against RSV on the market for a long time called Synagis, given to premies and young high risk children. I don't know enough about the differences between the two monoclonals but I agree with Dew, should have little to no impact on ENTA.
Market Data 
Markets 
AI
